Absolute Counts of Lymphoid Cells in the Blood of BM and PBSC Recipients at 2 Months After Transplantation as Well as in the BM and PBSC Grafts
| . | Absolute Blood Counts of Cells (×106/L) at 2 mo After Grafting* . | Absolute Numbers of Cells (×106) in the Grafts . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | BM Recipients . | PBSC Recipients . | PBSC/BM . | P Value† . | BM Grafts . | PBSC Grafts . | PBSC/BM Ratio‡ . | P Value† . |
| . | (n = 29) . | (n = 20) . | Ratio . | . | (n = 15) . | (n = 18) . | . | . |
| Naive CD4 T cells (CD45RAhigh CD4+ CD3+) | 6 | 37 | 6.2 | <.001 | 370 | 4,210 | 11.4 | <.001 |
| (0-85) | (3-374) | (28-1,210) | (1,436-10,003) | [16.0] | ||||
| Memory CD4 T cells (CD45RAlow/neg CD4+ CD3+) | 49 | 77 | 1.6 | .091 | 354 | 7,370 | 20.8 | <.001 |
| (6-407) | (13-693) | (85-1,246) | (4,645-11,929) | [29.1] | ||||
| CD8 T cells (CD8+ CD3+) | 35 | 39 | 1.1 | .911 | 559 | 3,952 | 7.1 | <.001 |
| (0-1,634) | (2-414) | (119-1,774) | (330-10,620) | [9.9] | ||||
| Double-negative T cells (CD3+ CD4− CD8−) | 5 | 12 (1-92) | 2.4 | .043 | 26 | 440 | 16.9 | <.001 |
| (0-23) | (5-236) | (107-1,445) | [23.7] | |||||
| Naive B cells (mIgD+ CD19/20+ CD3/13/14/16/56−)ρ | 1 | 7 | 7.0 | .003 | 159 | 2,947 | 18.5 | <.001 |
| (0-48) | (0-242) | (16-1,529) | (2,039-6,561) | [25.9] | ||||
| Memory B cells (mIgD− CD19/20+ CD3/13/14/16/56−)ρ | 0.3 | 1.1 | 3.7 | <.001 | 51 | 662 | 13.0 | <.001 |
| (0-3.1) | (0.1-10.1) | (6-209) | (202-1,522) | [18.2] | ||||
| B-cell precursors (CD10/34+ CD19/20+ CD3/13/14/16/56−) | Not done | Not done | — | — | 224 | 0 | 0 | <.001 |
| (6-1,365) | (0-163) | [0] | ||||||
| Plasma cells (CD38high) | Not done | |||||||
| Not done | ||||||||
| — | — | |||||||
| 26 | 0 | 0 | <.001 | |||||
| (4-149) | (0-62) | [0] | ||||||
| Total IgG in serum (g/L)2-155 | 5.7 | 4.7 | 0.8 | .054 | Not done | |||
| (2.8-14.8) | (2.4-12.9) | |||||||
| Not done | ||||||||
| — | ||||||||
| — | ||||||||
| . | Absolute Blood Counts of Cells (×106/L) at 2 mo After Grafting* . | Absolute Numbers of Cells (×106) in the Grafts . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | BM Recipients . | PBSC Recipients . | PBSC/BM . | P Value† . | BM Grafts . | PBSC Grafts . | PBSC/BM Ratio‡ . | P Value† . |
| . | (n = 29) . | (n = 20) . | Ratio . | . | (n = 15) . | (n = 18) . | . | . |
| Naive CD4 T cells (CD45RAhigh CD4+ CD3+) | 6 | 37 | 6.2 | <.001 | 370 | 4,210 | 11.4 | <.001 |
| (0-85) | (3-374) | (28-1,210) | (1,436-10,003) | [16.0] | ||||
| Memory CD4 T cells (CD45RAlow/neg CD4+ CD3+) | 49 | 77 | 1.6 | .091 | 354 | 7,370 | 20.8 | <.001 |
| (6-407) | (13-693) | (85-1,246) | (4,645-11,929) | [29.1] | ||||
| CD8 T cells (CD8+ CD3+) | 35 | 39 | 1.1 | .911 | 559 | 3,952 | 7.1 | <.001 |
| (0-1,634) | (2-414) | (119-1,774) | (330-10,620) | [9.9] | ||||
| Double-negative T cells (CD3+ CD4− CD8−) | 5 | 12 (1-92) | 2.4 | .043 | 26 | 440 | 16.9 | <.001 |
| (0-23) | (5-236) | (107-1,445) | [23.7] | |||||
| Naive B cells (mIgD+ CD19/20+ CD3/13/14/16/56−)ρ | 1 | 7 | 7.0 | .003 | 159 | 2,947 | 18.5 | <.001 |
| (0-48) | (0-242) | (16-1,529) | (2,039-6,561) | [25.9] | ||||
| Memory B cells (mIgD− CD19/20+ CD3/13/14/16/56−)ρ | 0.3 | 1.1 | 3.7 | <.001 | 51 | 662 | 13.0 | <.001 |
| (0-3.1) | (0.1-10.1) | (6-209) | (202-1,522) | [18.2] | ||||
| B-cell precursors (CD10/34+ CD19/20+ CD3/13/14/16/56−) | Not done | Not done | — | — | 224 | 0 | 0 | <.001 |
| (6-1,365) | (0-163) | [0] | ||||||
| Plasma cells (CD38high) | Not done | |||||||
| Not done | ||||||||
| — | — | |||||||
| 26 | 0 | 0 | <.001 | |||||
| (4-149) | (0-62) | [0] | ||||||
| Total IgG in serum (g/L)2-155 | 5.7 | 4.7 | 0.8 | .054 | Not done | |||
| (2.8-14.8) | (2.4-12.9) | |||||||
| Not done | ||||||||
| — | ||||||||
| — | ||||||||
Values are expressed as the median (range).
The absolute blood counts of all the lymphocyte subsets in the PBSC recipients as well as in the BM recipients were significantly lower than those in healthy adult controls6 7 (P < .05, Wilcoxon-Mann-Whitney rank-sum test).
P value for the difference between BM and PBSC recipients (grafts); tested by Wilcoxon-Mann-Whitney rank-sum test.
The numbers in brackets represent corrected PBSC/BM ratio, ie, the raw PBSC/BM ratio multiplied by 1.40 because 40% (8/20) PBSC recipients received 2 instead of 1 mononuclear cell apheresis products (PBSC grafts). Here it is assumed that the second product contained approximately the same amount and subset distribution of lymphoid cells as the first product. The second apheresis product was infused on day 0 or 1. Interestingly, there was a trend towards increased blood counts of naive CD4 T cells at 2 months after grafting in the 8 patients receiving 2 apheresis products compared with the 12 patients receiving only 1 apheresis product (median 66 v 16 × 106/L; P = .105).
ρ In the marrow and PBSC grafts, naive B cells were defined as mIgD+ CD19/20+ CD3/10/13/14/16/34/56− and memory B cells as mIgD− CD19/20+ CD3/10/13/14/16/34/56− to avoid counting B-cell precursors as B cells.
Measured on approximately day 80. Patients treated with intravenous Ig (3 in BMT group and 4 in PBSCT group) were excluded from the calculation. Normal range (5th-95th percentile): 6.94 to 15.18 g/L.